Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.

Bone Metastases

HER2-positive Breast Cancer

Liver Metastases

Lung Metastases

Recurrent Breast Cancer

Soft Tissue Metastases

Stage IV Breast Cancer

fludeoxyglucose F 18

positron emission tomography

computed tomography

trastuzumab

copper Cu 64-DOTA-trastuzumab

ado-trastuzumab emtansine

laboratory biomarker analysis

City of Hope Medical Center

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine

Will be correlated with subsequent tumor response to ado-trastuzumab emtansine using a t-test with a 0.05 two-sided significance level.

Will be correlated with uptake of copper Cu 64-DOTA-trastuzumab using a t-test with a 0.05 two-sided significance level.

Will be compared between "responding" and "non-responding" tumors using a t-test with 0.05 one-sided significance level.

Tissue samples will be used to explore the correlation between the presence of MMRs as assessed by histopathology and tumor response to ado-trastuzumab emtansine both in univariate analysis and in combination with tumor uptake of copper Cu 64-DOTA-trastuzumab as measured with PET/CT

National Cancer Institute (NCI)

PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.

Breast Cancer

PET images performed on a GE Discovery 16 Ste PET-CT scanner

15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.

acetic acid/ailse chíche

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Early Detection of Breast Cancer and Cervical Cancer in Women in India

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht